New book series brings updated reviews on diabetes and obesity

Frontiers in Clinical Drug Research - Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases - diabetes and obesity.

The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology, and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity.

Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents.

Frontiers in Clinical Drug Research - Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The fifth volume of this series features 5 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist.

  • Metabolic syndrome in schizophrenia
  • Insulin therapy and foetoplacental endothelial dysfunction in gestational diabetes mellitus
  • Insights on diabetes, oxidative stress, and antioxidant therapeutic strategies
  • Administration of Nano drugs in the treatment of diabetes mellitus
  • SGLT-2 inhibitors

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide may lower Alzheimer's risk in type 2 diabetes patients